ctDNA sensitivity in early-stage disease



Published
Bruna Pellini, MD, Moffitt Cancer Center, Tampa, FL, discusses remaining challenges in implementing circulating tumor DNA (ctDNA)-based approaches in clinical practice, highlighting difficulties in detecting early-stage disease which may result in false negatives. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
Category
Health
Be the first to comment